Bevacizumab Plus Temozolomide Produces Low Response in Newly-Diagnosed Glioblastoma
Combination bevacizumab with radiotherapy and temozolomide is safe in glioblastoma, but low response rates do not favor a neoadjuvant approach.
Diagnosis & Disease Information
VAL-083 Shows Promise for Glioblastoma Multiforme
Phase 2 studies show in vitro effectiveness in various glioblastoma multiforme cell lines, independent of MGMT activity.
Bevacizumab at Half the Standard Dose Equivalent to Standard Dosing for Glioblastoma
Bevacizumab at half the standard dose for the treatment of patients with progressive or recurrent glioblastoma.
AZD8055 Plus Temozolomide Effective for Glioblastoma in Preclinical Study
A novel drug called AZD8055 plus temozolomide extended the life of animals with human brain tumors by 30%.
Bevacizumab Does Not Improve Survival in Newly-Diagnosed Glioblastoma
Among patients with newly-diagnosed glioblastoma, adding bevacizumab to standard first-line chemoradiotherapy does not improve survival, found data presented at ASCO 2013.
Surgery Doesn’t Up Pediatric Neuroblastoma Outcomes
For pediatric patients with stage 4 neuroblastoma, surgery of the primary tumor site has no impact on outcomes.
Survival Data Announced for Rindopepimut in Glioblastoma
Celldex Therapeutics announced three-year survival data from the Phase 2 rindopepimut clinical program in EGFRvIII-positive glioblastoma—a more aggressive form of glioblastoma typically associated with reduced long-term survival in comparison to the glioblastoma population as a whole.
Chemoradiotherapy Improves OS in Anaplastic Oligodendroglioma
Procarbazine, lomustine, and vincristine (PCV) plus radiotherapy (RT) “may be an especially effective treatment” for a subset of patients with 1p/19q co-deleted anaplastic oligodendrogliomas, both pure (AO) and mixed (anaplastic oligoastrocytoma [AOA]).
New Susceptibility, Progression Loci Identified for Childhood Neuroblastoma
Two new genetic associations with neuroblastoma risk and progression have been identified, both at 6q16.
Non-CNS Childhood Cancer Linked to Developmental Delays
Very young children who undergo treatment for non-CNS cancers manifest deficits in motor, mental, and language development but are similar in cognitive representational abilities and emotional relationships in interaction with their mothers compared to healthy controls.
- Loading...
Loading...
Loading... 
Loading...